Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial
Authors' conclusion
Early administration of SC insulin degludec in combination with IVII accelerated DKA resolution and improved blood glucose levels at 72 h in patients with rebound hyperglycaemia after discontinuation of IVII, without increasing the risk of hypoglycaemia or hypokalaemia.
Study context
- Population
- Adults (≥18 years) with diabetic ketoacidosis (DKA); 67.5% had T2D
- Participants
- 80 adults
- Comparison
- Early subcutaneous (SC) insulin degludec plus intravenous insulin infusion (IVII) vs IVII alone
- Primary endpoint
- Time to DKA resolution
Methodological detailsprospective, open-label
- Prospective
- Open-label
Primary result
As reported in the abstract
Difference
3.25 h
P = 0.039
By group
Secondary outcomes
Mean capillary blood glucose · 72 h after transition to SC insulin · lower with early degludec
P = 0.012
Rebound hyperglycaemia at 12 h after bridging, mean capillary blood glucose (CBG) at 12, 24 and 48 h in those with rebound hyperglycaemia, LOS
- Not significantly different between groups
Safety
Rebound DKA, hypoglycaemia, hypokalaemia, in-hospital mortality
- Not significantly different between groups
Original publication
Early insulin degludec with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial. Diabetes Obes Metab. Published 3 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →